Recombinant Human MDMX/MDM4 protein (GST tag N-Terminus)

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The MDMX protein also known as MDM4 is an important regulator in the control of the p53 tumor suppressor pathway. Typically MDMX can be found expressed in multiple tissue types including the brain and kidney. MDMX with a molecular mass of approximately 54 kDa functions as an E3 ligase that binds to the p53 protein inhibiting its transcriptional activity and promoting its degradation. This precise interaction with p53 allows the regulation of cell growth and apoptosis making MDMX an important target for cancer research.

Biological function summary

MDMX contributes significantly to cell cycle regulation and apoptosis by forming a complex with MDM2 another E3 ubiquitin ligase. Together with MDM2 MDMX modulates the stability and activity of p53 therefore influencing cell fate decisions. This complex is important in preventing unwarranted p53 activity ensuring that the cell only undergoes apoptosis or cell cycle arrest in response to specific stress signals.

Pathways

The MDMX protein plays a central role in the p53 signaling pathway a critical mechanism in cellular response to genomic damage. It interacts directly with MDM2 to regulate p53's activity maintaining a balance between cell proliferation and death. This pathway is tightly linked to the DNA damage response providing a checkpoint during the cell cycle to prevent the propagation of genetically unstable cells. Additionally MDMX influences the PI3K/AKT pathway further intertwining its function with cellular survival processes.

The deregulation of MDMX is often associated with various forms of cancer including breast and colorectal cancers. Overexpression or genetic amplification of MDMX can lead to impaired p53 activity which promotes cell survival and proliferation in the presence of DNA damage. MDMX has a close connection with MDM2 in these disease contexts as both proteins synergize to inhibit p53 contributing to tumorigenesis. Therapeutic targeting of MDMX and its interaction with MDM2 offers a potential strategy for reinstating p53 activity in cancer treatment.